Expert Analysis

Focus on Investigational HBV/HCV Agents

Source: CCO Official Conference Coverage of the 2008 AASLD Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Focus on Investigational HBV/HCV Agents

Faculty:

Nezam H. Afdhal, MD, FRCPI
Fred Poordad, MD
Stefan Zeuzem, MD

CREDIT INFORMATION

Release Date: 01/08/09

Expiration Date: 01/07/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing contact hours

Pharmacists: 1.25 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data on the use of protease inhibitors for the treatment of HCV infection
Recount data on novel polymerase inhibitors for the treatment of HCV infection
Describe the role of ribavirin and/or ribavirin analogues with HCV treatments in development
Describe new data on novel agents in development for the treatment of HBV infection

Topics covered include:

Clevudine in Treatment-Naive Patients With Chronic HBV Infection
Telaprevir Plus Peginterferon alfa-2a/Ribavirin in Treatment-Naive Genotype 1 HCV–Infected Patients
Telaprevir and Peginterferon alfa-2a/Ribavirin in Treatment-Experienced Genotype 1 HCV–Infected Patients
Telaprevir Once vs Twice Daily With Ribavirin and Either Peginterferon alfa in HCV Genotype 1 Treatment-Naive Patients
Boceprevir and Peginterferon alfa-2b/Ribavirin in Treatment-Naive Genotype 1 HCV–Infected Patients
MK-7009 Monotherapy in Treatment-Naive and -Experienced Genotype 1 HCV–Infected Patients
BI201335 Monotherapy in Treatment-Naive Genotype 1 HCV–Infected Patients
PF-00868554 Monotherapy Dose Escalation in Interferon-Naive Genotype 1 HCV–Infected Patients
R7128 Plus Peginterferon alfa-2a/Ribavirin in Treatment-Naive Genotype 1 HCV–Infected Patients
R7128 Plus Peginterferon alfa-2a/Ribavirin in Treatment-Experienced Genotype 2/3 HCV–Infected Patients
Weight-Based Taribavirin vs Weight-Based Ribavirin in Treatment-Naive Genotype 1 HCV–Infected Patients
Summary

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.